Chesapeake IRB Acquires Institutional Biosafety Corporation

June 6, 2017
Applied Clinical Trials

Chesapeake IRB, the technology-enabled independent institutional review board (IRB) serving the clinical research industry, announced its acquisition of Institutional Biosafety Corporation (IBC), a provider of institutional biosafety committee services located in Rockville, MD.

The acquisition now expands Chesapeake’s services with the ability to deliver comprehensive review and oversight of research using recombinant or synthetic DNA molecules, including clinical trials involving genetic engineering and gene therapy.

Read the full release here.